A Phase I /II Study of Tri-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: XELIRI+ bevacizumab Primary outcome(s): Phase I part Estimated the dose limiting toxicities in 1st cycle. Phase II part Progressiom Free Survival Study Design: Single arm Non-randomized
创建时间：
2010-05-15
